Medical Device Tax
The Affordable Care Act (“Obamacare”) imposed a 2.3% excise tax on medical devices, to be paid by medical products manufacturers, producers, and importers. A two-year moratorium on the tax began in December 2015. HIDA supports the permanent repeal of the tax.
The tax would apply to all regulated Food and Drug Administration (FDA) Class I, Class II, and Class III medical devices, with the exception of those products, “determined by the Secretary to be of a type which his generally purchased by the general public at retail for individual use,” including eye glasses, contacts, and hearing aids.
What Members Need to Know
In addition to supporting the moratorium/repeal, HIDA supports the Internal Revenue Service’s final regulation which included many changes important to HIDA members – specifically, the retail exemption. The exemption reduces some of the burden faced by the supply chain industry, such as:
- The inclusion of medical supply stores and specialty medical stores in the definition of retail.
- Deeming purchases made by consumers via the internet or over the phone as retail.
- The acceptances of further examples of products that meet the retail exemption criteria, thereby providing additional insight into how the agency expands manufacturers to make determinations.
“Convenience kits” that include various medical products in a single package were source of confusion when the law was first enacted. The IRS released Interim Guidance clarifying that while domestically assembled convenience kits are exempt from the medical device tax, imported convenience kits are subject to the device tax – but only the amount allocable to the individual taxable medical devices within the kit.
A delay of the medical device tax was passed in a major omnibus bill at the end of 2015. While full repeal has been included in several pieces of legislation none have made it to the president’s desk. The current delay expires at the end of 2017.
HIDA believes the excise tax on medical devices threatens U.S. jobs, impacts healthcare costs and stifles innovation. Now, more than ever, we must strengthen the businesses that support patient care and our economy.